UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology... ( COLLEGE PARK Md. Feb. 21 -- The ...)

HOME >> MEDICINE >> TECHNOLOGY

UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies

Date:2/21/2008

COLLEGE PARK, Md., Feb. 21 /PRNewswire-USNewswire/ -- The University of Maryland's Maryland Industrial Partnerships Program (MIPS) today announces the approval of 18 new collaborative research projects between Maryland companies and university faculty.

Worth $4.4 million, the new projects combine $3 million from participating companies and $1.4 million from the Maryland Industrial Partnerships Program.

Through MIPS, faculty members engage in research that furthers the development of high-tech products for Maryland companies. Projects, which must be technology-focused and possess commercial potential, can range from creating or testing new products to clinical and pre-clinical trials.

Both the company and the University of Maryland contribute funding for each project. All funding goes to the participating faculty.

Four University System of Maryland campuses have approved projects. Three participating companies are based in Baltimore, two are on the Eastern Shore, one is in Southern Maryland, and one is near Annapolis, while the remaining ten are in Frederick, Gaithersburg, and near the Capital Beltway.

Projects approved, listed by participating company, university, project title and total project funding, include:

-- Salisbury-based AHPharma Food Safety Products Inc. and the University of Maryland Eastern Shore: Underwater Pulsed Arc Discharge (UPAD) for Poultry; $251,703

-- Arnold-based Applied Sensor Research and Development Corp. and the University of Maryland, College Park: Porous Packaging for Microfluidic Sensors; $97,112.

-- Frederick-based BioElectronics Corporation and the University of Maryland, Baltimore: Pulsed Electromagnetic Therapy for Healing; $258,788.

-- Baltimore-based CCC Diagnostics LLC and the University of Maryland, Baltimore: Clinical Studies of Drug Response Indicators Test; $732,700.

-- Baltimore-based CSA Medical Inc. and the University of Maryland, Balti
'/>"/>

SOURCE University of Maryland
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
2. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
3. UCLA Program Aims to Revolutionize Kidney Transplants
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
8. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
9. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
10. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...

(Date:6/19/2013)... DIEGO , June 19, 2013 Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain. This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...

(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...

[0] Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer [0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence [0] NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease

... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...

... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...

Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2 REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2 REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3

Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011

(Date:6/19/2013)... along with the Japanese government and the Bill ... bolster Japan,s contribution to global health through the ... a press conference held as a side event ... Development (TICAD V). , Representatives from each of ... Labour and Welfare, the Ministry of Foreign Affairs, ...

(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...

(Date:6/19/2013)... Ariz. (PRWEB) June 19, 2013 PREFERRED ... WellCare of Arizona to offer a new ... Maricopa, Pima, La Paz, Yavapai and Mohave, Arizona counties. ... Mohave counties were effective January 1, 2013 and Maricopa ... 2014. , WellCare, Inc., the parent company of WellCare ...

(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...

(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... go to bed or rise early thanks to a new ... , Crafty travelers will have a little extra change in ... Paradise Valley hotel’s Book Early and Save Up to ... notice, guests can enjoy the year-round Scottsdale sunshine in deluxe ...

Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3 Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2 Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3 Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3 Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2 Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3 Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4

[0] GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health [0] Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations [0] PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network [0] Brightree Debuts on List of Top 100 Healthcare Technology Companies [0] Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley

... of the BBVA Foundation, Francisco Gonzlez, Jose Baselga, ... Center (MGHCC), and Andrs de Kelety, Managing Director ... in Barcelona, yesterday signed the agreement creating the ... the event was the Foundation,s Director, Mr. Rafael ...

... (HealthDay News) -- Women and younger men account for a ... are less likely than older men to receive preventive medications ... Researchers evaluated more than 3,000 heart attack patients treated at ... and found that 70.3 percent of them had not been ...

... study to investigate the tolerability of the breast cancer drug ... stop taking their prescribed therapy early because of problems with ... of the research paper, published today in the cancer journal ... 64 male breast cancer patients at their institution who had ...

... rely on recombinant, protein-based drugs must often endure ... intravenous therapy. Researchers at Children,s Hospital Boston demonstrate ... engineered cells, could secrete the drug on demand ... issue of the journal Blood , they ...

... By Randy Dotinga HealthDay Reporter , TUESDAY, ... whole-body vibration doesn,t appear to improve the bone health ... osteoporosis. The treatment -- which involves standing on a ... -- showed promise in animals. But researchers, who hoped those ...

... read will be one of the topics of a conference ... co-sponsored by the UC Davis Center for Mind and Brain, ... Visual Learning, and the departments of psychology and linguistics at ... to read, said David Corina, professor in the Department of ...

Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2 Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3 Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2 Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2 Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3 Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2 Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3 Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2 Health News:Visual language, cognition and deaf education topics of summit 2

Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance Women, Younger Men Under-Treated Before Heart Attack: Study Male breast cancer patients stop taking tamoxifen early because of drug-related side effects Engineered, drug-secreting blood vessels reverse anemia in mice Whole-Body Vibration Doesn't Build Bone After All: Study Visual language, cognition and deaf education topics of summit

... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...

... The POLARstar OPTIMA is a fully ... incorporates five different measurement principles:, , ... , Time-Resolved Fluorescence , High-Performance ... Absorbance ,It is designed ...

... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...

The basic modular Wallac 1420 VICTOR2 is a manually operated platereader which enables luminometry, fluorometry and photometry measurements to be made....

Medicine Products:

Analyst AD (Non-Stacker Configuration)POLARstar OPTIMA Genios Multi-Detection Microplate Reader Basic modular VICTOR2 Multilabel Counter (3 technologies)